TICKERNOMICS Sign up
Last Update: 2024-12-27 15:29:03
Cara Therapeutics Inc. ( CARA ) https://www.caratherapeutics.com
0.45USD
Sector:
Healthcare
Industry:
Biotechnology
Country:
United States
1y
3y
5y
10y
Historical Returns*:
SPY
27.80%
-41.36%
CARA
SPY
32.66%
-96.33%
CARA
SPY
108.59%
-97.29%
CARA
SPY
302.52%
-95.48%
CARA
*Assumes dividends reinvested
Market Stats:
Market Capitalization($MM)
Enterprise Value($MM)
Daily Volume(MM)
23.18
-11.37
0.83
Valuation Metrics:
Price/Earnings Ratio
Price/Sales Ratio
Price/Book Value
FCF Yield(%)
Dividend Yield(%)
EV/EBITDA
-0.24
2.67
32.78
-464.63
0.00
0.19
Profitability Stats:
Operating Margin %(ttm)
Gross Profit %(ttm)
EBITDA Margin %(ttm)
-234.27
100.00
-712.35
Shareholder Value Creation:
Cost of Capital %(est)
ROIC %(ttm)
ROCE %(ttm)
Beta
7.9632
-66.30
-45.51
0.99
Other Earnings and Cash Flow Stats:
Cara Therapeutics Inc. ( CARA ) Net Income TTM ($MM) is -95.53
Cara Therapeutics Inc. ( CARA ) Operating Income TTM ($MM) is -85.57
Cara Therapeutics Inc. ( CARA ) Owners' Earnings Annual ($MM) is -94.98
Cara Therapeutics Inc. ( CARA ) Current Price to Owners' Earnings ratio is -0.42
Cara Therapeutics Inc. ( CARA ) EBITDA TTM ($MM) is -85.29
Cara Therapeutics Inc. ( CARA ) EBITDA Margin is -712.35%
Capital Allocation:
Cara Therapeutics Inc. ( CARA ) has paid 0.00 dividends per share and bought back -0.608146 million shares in the past 12 months
Cara Therapeutics Inc. ( CARA ) has increased its debt by 0.176 million USD in the last 12 months
Capital Structure:
Cara Therapeutics Inc. ( CARA ) Interest-bearing Debt ($MM) as of last quarter is 7
Cara Therapeutics Inc. ( CARA ) Annual Working Capital Investments ($MM) are 3
Cara Therapeutics Inc. ( CARA ) Book Value ($MM) as of last quarter is 0
Cara Therapeutics Inc. ( CARA ) Debt/Capital as of last quarter is 64%
Other Balance Sheet Stats:
Cara Therapeutics Inc. ( CARA ) has 37 million in cash on hand as of last quarter
Cara Therapeutics Inc. ( CARA ) has 10 million of liabilities due within 12 months, and long term debt 0 as of last quarter
Cara Therapeutics Inc. ( CARA ) has 54 common shares outstanding as of last quarter
Cara Therapeutics Inc. ( CARA ) has 0 million USD of preferred stock value
Academic Scores:
Cara Therapeutics Inc. ( CARA ) Altman Z-Score is -22.87 as of last quarter
Cara Therapeutics Inc. ( CARA ) Piotroski Score is 4.00 as of last quarter
Corporate Governance:
Cara Therapeutics Inc. ( CARA ) largest shareholder is NewEdge Advisors, LLC owning 1165 shares at 0.00 ($MM) value
Posner Christopher(an insider) Sold 3668 shares of Cara Therapeutics Inc. ( CARA ) for the amount of $1063.72 on 2024-11-04
15.74% of Cara Therapeutics Inc. ( CARA ) is held by insiders, and 28.16% is held by institutions
Cara Therapeutics Inc. ( CARA ) went public on 2014-01-31
Other Cara Therapeutics Inc. ( CARA ) financial metrics:
FCF:-77.55
Unlevered Free Cash Flow:-204.22
EPS:-0.91
Operating Margin:-234.27
Gross Profit Margin:100.00
Div. Payout Ratio%:0.00
Div. Growth YoY%:0.00
Equity Return%:-7058.56
Beta:0.99
Buffet's Owners Earnings:-94.98
Price to Owner's Earnings:-0.42
About Cara Therapeutics Inc. ( CARA ) :
Cara Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapeutics treatment of pruritus in the United States. The company's lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis. Its product candidate, including Oral KORSUVA (difelikefalin), which has completed Phase II clinical trial to treat pruritus atopic dermatitis and pruritus non-dialysis-dependent chronic kidney disease (NDD-CKD) associated pruritus; and in Phase II clinical trial to treat pruritus chronic liver disease (CLD) primary biliary cholangitis (PBC) and notalgia paresthetica. Cara Therapeutics, Inc. has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing difelikefalin for acute pain and uremic pruritus in Japan; Vifor Fresenius Medical Care Renal Pharma Ltd. and Winhealth Pharma for the co-development and commercialization of KORSUVA injection for the treatment of moderate-to-severe pruritus in adult patients undergoing hemodialysis in China; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing difelikefalin in South Korea. The company was incorporated in 2004 and is based in Stamford, Connecticut.
User Content from Tickernomics. Created by Luminus.
DISCLAIMER

This web site and its creators are not certified financial advisors. All opinions/suggestions expressed on this website should not be treated as specific inducement to make a particular investment or follow a particular strategy, but only as an expression of an opinion.The Company doesn't warrant the information provided on the website for its completeness or accuracy, and it should not be relied upon as such. The Company is not under any obligation to update or correct any information provided on this website.The content of this website is published in the United States of America and persons who access it agree to do so in accordance with applicable U.S. law.Past performance is not indicative of future results. The Company doesn't guarantee any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment discussed on this website.Strategies or investments discussed may fluctuate in price or value. Investors may get back less than invested. Investments or strategies mentioned on this website may not be suitable for you. This material does not take into account your particular investment objectives,financial situation or needs and is not intended as recommendations appropriate for you. You must make an independent decision regarding investments or strategies mentioned on this website. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.